Identification of a stool long non-coding RNAs panel as a potential biomarker for early detection of colorectal cancer

• Main Authors: Asadzadeh Aghdaei, H. (Author), Baghdar, K. (Author), Gharib, E. (Author), Hashemi, M. (Author), Jamshidi-Fard, A. (Author), Larki, P. (Author), Nayeri, Z. (Author), Nazemalhosseini-Mojarad, E. (Author), Rezasoltani, S. (Author), Sadeghi, A. (Author), Sadeghi, H. (Author)
• Format: Article
• Language: English
• Published: John Wiley and Sons Inc 2021
• Subjects: adult; Adult; advanced cancer; Article; biomarker; Biomarkers, Tumor; cancer staging; cohort analysis; colon cell; colon polyp; Colonic Polyps; colorectal cancer; Colorectal Neoplasms; colorectal tumor; controlled study; early cancer diagnosis; Early Detection of Cancer; fecal colonocytes; feces; Feces; feces analysis; female; Female; gene expression; gene expression regulation; Gene Expression Regulation, Neoplastic; gene sequence; genetics; human; human cell; Humans; isolation and purification; long non-coding RNAs; long untranslated RNA; long untranslated RNA CCAT1; long untranslated RNA CCAT2; long untranslated RNA H19; long untranslated RNA HOTAIR; long untranslated RNA HULC; long untranslated RNA MALAT1; long untranslated RNA MEG3; long untranslated RNA PCAT1; long untranslated RNA PTENP1; long untranslated RNA TUSC7; major clinical study; male; Male; middle aged; Middle Aged; prediction; quality control; real time polymerase chain reaction; reproducibility; Reproducibility of Results; RNA analysis; RNA extraction; RNA isolation; RNA, Long Noncoding; tumor marker; unclassified drug; validation study
• Online Access: View Fulltext in Publisher

 Background: The feces of colorectal cancer (CRC) patients contain tumor colonocytes, which constantly shed into the lumen area. Therefore, stool evaluation can be considered as a rapid and low-risk way to directly determine the colon and rectum status. As long non-coding RNAs (lncRNAs) alterations are important in cancer cells fate regulation, we aimed to assess the level of a panel of cancer-related lncRNAs in fecal colonocytes. Methods: The population study consisted of 150 subjects, including a training set, a validation set, and a group of 30 colon polyps. The expression levels of lncRNAs were evaluated by quantitative real-time PCR (qRT-PCR). The NPInetr and EnrichR tools were used to identify the interactions and functions of lncRNAs. Results: A total of 10 significantly dysregulated lncRNAs, including CCAT1, CCAT2, H19, HOTAIR, HULC, MALAT1, PCAT1, MEG3, PTENP1, and TUSC7, were chosen for designing a predictive panel. The diagnostic performance of the panel in distinguishing CRCs from the healthy group was AUC: 0.8554 in the training set and 0.8465 in the validation set. The AUC for early CRCs (I-II TNM stages) was 0.8554 in the training set and 0.8465 in the validation set, and for advanced CRCs (III-IV TNM stages) were 0.9281 in the training set and 0.9236 in the validation set. The corresponding AUC for CRCs vs polyps were 0.9228 (I-IV TNM stages), 0.9042 (I-II TNM stages), and 0.9362 (III-IV TNM stages). Conclusions: These data represented the application of analysis of fecal colonocytes lncRNAs in early detection of CRC. © 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals LLC.